Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M. Younossi, Victor Ankoma‐Sey, David Sheridan et al.|The Lancet|2019Cited by 1.2k
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with RibavirinJordan J. Feld, Barry Bernstein, Kris V. Kowdley et al.|New England Journal of Medicine|2014Cited by 907
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile InfectionSahil Khanna, Paul Feuerstadt, Maha Assi et al.|Drugs|2022Cited by 273
Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile InfectionSahil Khanna, Paul Feuerstadt, Maha Assi et al.|Drugs|2022Cited by 6
Tu1515: CLIMB: A PROSPECTIVE, BLINDED, MULTICENTER U.S. BASED STUDY EVALUATING A MULTI-ANALYTE BLOOD-BASED TEST FOR DETECTING HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH LIVER CIRRHOSISDavid J. Taggart, Mindie H. Nguyen, Shivani Mahajan et al.|Gastroenterology|2025Cited by 1